{
  "docId": "019de070-da34-70fa-b6ea-612c42635c34",
  "docSlug": "1519080da03b1584f82c21fb8b213d00",
  "documentTitle": "Alkermes | Results Presentation Deck | 13 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 13,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 9,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-da34-70fa-b6ea-612c42635c34/10",
  "deckHref": "/decks/019de070-da34-70fa-b6ea-612c42635c34",
  "deckJsonHref": "/decks/019de070-da34-70fa-b6ea-612c42635c34.json",
  "deckAnchorHref": "/decks/019de070-da34-70fa-b6ea-612c42635c34#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ARISTADA Quarterly TRx MOT",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa98be60-71fd-4d9c-944c-2b19664992ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Q1 year-over-year growth of 11% on TRx months of therapy (MOT) basis; Outpaced overall atypical long-acting injectable (LAI) market Q1 year-over-year growth of 3%. Market share: TRx MOT: 9.2% of atypical LAI market prescriptions in Q1'21",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f406256e-5900-42cc-a1b5-92b719abd20d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Source: IQVIA NPA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a7fd066-3cfd-4500-a77d-258b03d03594",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "ARISTADA®: Prescription Growth Trends",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80275a81-b775-4b5b-905b-74dca949ef11",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 8,
      "beatId": "dc1e817b-ccb6-46ff-9d55-12e11fdd9972",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product performance",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 8-10 discuss the performance and expectations of VIVITROL and ARISTADA",
      "position": 1,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}